Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- An Attractive Target
- Overview of PAH
- Disease Characteristics, Diagnosis, and Prevalent Cases
- Risk Factors, Disease Pathways, and Drug Targets
- Approved Drug Therapies
- Flolan
- Tracleer
- Revatio
- Remodulin
- Ventavis
- Other Drug Therapies
- Combination Therapy
- Promising New Therapies
- Novel Endothelin Receptor Antagonists: Ambrisentan vs Thelin
- Reformulated Prostacyclin Analogues: Inhaled and Oral Remodulin
- PDE-5 Inhibitors: Cialis, Levitra, and UK-369003
- Vasoactive Intestinal Peptide Derivatives: Aviptadil
- Serotonin Pathway Antagonists: PRX-08066 and Cipralex/Lexapro
- Tyrosine Kinase Inhibitors: Gleevec
- Other Promising Pipeline Agents
- Outlook
- Market Drivers and Constraints
- Pulmonary Arterial Hypertension Market Through 2010
Tables
- 1. Prevalence of Pulmonary Arterial Hypertension, 2005
- 2. Molecular Targets for Current and Future PAH Therapies
- 3. Major Marketed Drugs for PAH
- 4. Emerging Therapies for the Treatment of Pulmonary Hypertension
- 5. Approval Status of Current PAH Therapies
- 6. Forecast of Regional Sales of Major PAH Drug Classes, 2010
Figures
- 1. Classifications of Pulmonary Arterial Hypertension
- 2. Risk Factors for Pulmonary Arterial Hypertension
- 3. Market Share of Current PAH Therapies in the Seven Major Markets, 2005
|
Related Report
|
View Cart
